| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.11μM (hRSV)[1].
RSV-IN-1 targets the human respiratory syncytial virus (hRSV), specifically the RSV fusion (F) protein. By targeting the F protein, the compound prevents the virus from entering host cells. It is classified as an RSV inhibitor with activity against hRSV. Its mechanism involves blocking viral entry and inhibiting viral replication. |
|---|---|
| ln Vitro |
The concentration of P13 that results in a 50% reduction (IC50) in the number of RSV plaques in HEp-2 cells is 0.11 μM. The concentration of P13 that causes a 50% reduction in HEp-2 viability (CC50) is 310 μM. Be aware that the DMSO solvent may be partially to blame for some of the P13 cytotoxicity seen at 500 μM. Therefore, P13's selective index (CC50/IC50) value is 2818. It should be noted that P13 does not totally prevent the formation of RSV plaques, even at the comparatively high concentrations. Compared to plaques formed in the absence of inhibitor, these escape plaques are smaller and have a non-syncytial phenotype[1].
In vitro, RSV-IN-1 inhibits hRSV with an IC50 of 0.11 μM. The concentration that results in a 50% reduction in RSV plaques in HEp-2 cells is 0.11 μM. The compound reduces virus infectivity in HEp-2 cells. Its potent activity against RSV makes it a valuable tool for studying RSV biology and developing new antiviral strategies. |
| ln Vivo |
In vivo, RSV-IN-1 has shown promise in preclinical studies for treating RSV infections. Its activity against RSV suggests potential for therapeutic applications, particularly in vulnerable populations such as infants, the elderly, and immunocompromised individuals. However, detailed in vivo efficacy and pharmacokinetic data are limited. Further studies are needed to fully characterize its in vivo potential.
|
| Enzyme Assay |
For non-cellular assays, RSV-IN-1 is evaluated for its ability to inhibit RSV fusion protein activity. Fusion inhibition is assessed using cell-free fusion assays or binding assays with purified RSV F protein. The compound's ability to prevent viral entry is evaluated using biochemical assays. IC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cell culture experiments are performed using HEp-2 cells infected with RSV. Cells are treated with RSV-IN-1 at concentrations ranging from 0.01 to 10 μM. Antiviral activity is assessed by plaque reduction assays, viral RNA quantification (qRT-PCR), or viral protein expression (immunofluorescence). IC50 values are calculated from dose-response curves. Cytotoxicity is evaluated using standard cell viability assays.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse models of RSV infection. RSV-IN-1 is administered intranasally, orally, or intraperitoneally. Efficacy is assessed by measuring viral titers in lungs, survival rates, body weight changes, and clinical signs of infection. Histopathological examination of lung tissue is performed to evaluate treatment response. Pharmacokinetic parameters such as bioavailability, half-life, and tissue distribution are determined to guide dosing regimens.
|
| ADME/Pharmacokinetics |
RSV-IN-1 has a molecular formula and weight as described in the literature. It is a small molecule with moderate lipophilicity. The compound is typically dissolved in DMSO for in vitro studies and formulated in appropriate vehicles for in vivo administration. Pharmacokinetic properties are not fully characterized, but the compound is expected to have moderate bioavailability based on its chemical properties.
|
| Toxicity/Toxicokinetics |
RSV-IN-1 shows an IC50 of 0.11 μM against hRSV. Its safety profile in preclinical studies suggests it is well-tolerated at effective doses. Standard laboratory safety precautions should be followed during handling. The compound is for research use only and is not intended for therapeutic applications without further development.
|
| References | |
| Additional Infomation |
RSV-IN-1 is an inhibitor of human respiratory syncytial virus (hRSV) with an IC50 of 0.11 μM. It targets the RSV fusion (F) protein, preventing viral entry and inhibiting replication. The compound has shown promise in preclinical studies for treating RSV infections. It is used in RSV research and is for research use only.
|
| Molecular Formula |
C20H21N5O4S
|
|---|---|
| Molecular Weight |
427.48
|
| Exact Mass |
427.131
|
| CAS # |
861139-16-4
|
| PubChem CID |
3943763
|
| Appearance |
Solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.685
|
| LogP |
3.53
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NN2C(=NN=C2C3=C(C=CC(=C3)S(=O)(=O)N(C)CCO)OC)C4=CC=CC=C14
|
| InChi Key |
RKHSOIYWKCMPHF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21N5O4S/c1-13-15-6-4-5-7-16(15)19-21-22-20(25(19)23-13)17-12-14(8-9-18(17)29-3)30(27,28)24(2)10-11-26/h4-9,12,26H,10-11H2,1-3H3
|
| Chemical Name |
N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (233.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3393 mL | 11.6965 mL | 23.3929 mL | |
| 5 mM | 0.4679 mL | 2.3393 mL | 4.6786 mL | |
| 10 mM | 0.2339 mL | 1.1696 mL | 2.3393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
